Matching articles for "page 6"
Issue 1330 · January 25, 2010 Free
Glucose Control in the ICU

Once thought to be a beneficial response to critical illness, hyperglycemia is now recognized as independently associated with death and other adverse outcomes in various groups of critically ill patients.…

Med Lett Drugs Ther. 2010 Jan 25; 52(1330):6-7
Once thought to be a beneficial response to critical illness, hyperglycemia is now recognized as independently associated with death and other adverse outcomes in various groups of critically ill patients. Whether normalization of blood glucose by insulin infusion is beneficial in such patients has been a subject of debate in the critical care community. Some new guidelines have been published. Click here to view the free full article.
Issue 1304 · January 26, 2009
Implantable Cardioverter Defibrillators

Implantable cardioverter defibrillators (ICDs) are widely used in patients at risk for sudden cardiac death (SCD) because these devices have been highly successful in terminating life-threatening ventricular…

Med Lett Drugs Ther. 2009 Jan 26; 51(1304):6-7
Implantable cardioverter defibrillators (ICDs) are widely used in patients at risk for sudden cardiac death (SCD) because these devices have been highly successful in terminating life-threatening ventricular arrhythmias and in increasing survival.
Issue 1252 · January 15, 2007
Dasatinib (Sprycel) for CML and Ph+ ALL

Dasatinib ( Sprycel - Bristol-Myers Squibb), an inhibitor of multiple tyrosine kinases, has been approved by the FDA for second-line treatment of chronic myelogenous leukemia (CML) and Philadelphia…

Med Lett Drugs Ther. 2007 Jan 15; 49(1252):6-7
Dasatinib ( Sprycel - Bristol-Myers Squibb), an inhibitor of multiple tyrosine kinases, has been approved by the FDA for second-line treatment of chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in adults.